Masayo Umebayashi
Fukuoka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Profiling immunogenic neoantigen peptides elicited by personalized neoantigen vaccine in cancer patients.
Journal: Frontiers in immunology
Published: March 13, 2026
Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study.
Journal: Frontiers in immunology
Published: February 05, 2025
Dendritic cell-derived exosomes induce monocyte antigen-presentation and immune amplification in neoantigen vaccine therapy.
Journal: Frontiers in immunology
Published: January 23, 2025
Inhibition of PTPN3 Expressed in Activated Lymphocytes Enhances the Antitumor Effects of Anti-PD-1 Therapy in Head and Neck Cancer, Especially in Hypoxic Environments.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: July 31, 2023
PTPN3 inhibition contributes to the activation of the dendritic cell function to be a promising new immunotherapy target.
Journal: Journal of cancer research and clinical oncology
Published: June 24, 2023
Corrigendum to "PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor" [Volume 14, Issue 9, September 2021, 101152].
Journal: Translational oncology
Published: January 18, 2022
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.
Journal: Immunological investigations
Published: September 06, 2021
TrkB/BDNF Signaling Could Be a New Therapeutic Target for Pancreatic Cancer.
Journal: Anticancer research
Published: May 22, 2021
Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.
Journal: Anticancer research
Published: May 22, 2021
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.
Journal: Translational oncology
Published: April 29, 2021
Last Updated: 09/26/2026